Related Experiment Videos
Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus
Francesca Santilli1, Giovanni Davì, Agostino Consoli
1Center of Excellence on Aging and Department of Medicine, University of Chieti G. D'Annunzio Schools of Medicine and Pharmacy, Chieti, Italy.
Journal of the American College of Cardiology
|January 18, 2006
Summary
Platelet activation, marked by thromboxane A2 (TXA2), drives soluble CD40 ligand (sCD40L) release in type 2 diabetes. Aspirin and improved metabolic control reduce these markers, suggesting therapeutic potential.
Area of Science:
- Cardiovascular Research
- Metabolic Disease Research
- Hematology
Background:
- Type 2 diabetes (T2DM) involves inflammation, oxidative stress, and platelet activation.
- CD40-CD40L interactions contribute to inflammatory and pro-thrombotic processes in T2DM.
Purpose of the Study:
- To characterize platelet contribution to soluble CD40 ligand (sCD40L) in T2DM.
- To correlate sCD40L formation with oxidative stress and platelet activation.
- To investigate the effects of improved metabolic control and aspirin on these markers.
Main Methods:
- Measured urinary 8-iso-prostaglandin F2alpha (oxidative stress) and 11-dehydro-thromboxane B2 (platelet activation) in T2DM patients and controls.
- Assessed plasma sCD40L and C-reactive protein (CRP) levels.
- Conducted studies on T2DM patients and healthy volunteers with varying aspirin doses and on T2DM patients with improved metabolic control.
Main Results:
- T2DM patients exhibited higher levels of oxidative stress, platelet activation, sCD40L, and CRP compared to controls.
- Platelet activation (11-dehydro-TXB2) and oxidative stress (8-iso-PGF2alpha) predicted sCD40L levels.
- Aspirin treatment reduced sCD40L and 11-dehydro-TXB2; improved metabolic control also lowered these markers.
Conclusions:
- sCD40L release in T2DM is dependent on thromboxane A2 (TXA2)-mediated platelet activation.
- Findings offer mechanistic insight into sustained platelet activation in T2DM.
- Therapeutic strategies targeting platelet activation may mitigate sCD40L-driven pathways in T2DM.